相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies
Linyuan Wang et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2022)
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Stephanie Lheureux et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer
Panagiotis A. Konstantinopoulos et al.
JAMA ONCOLOGY (2022)
To Test or Re-Test, that is the Question: Comparison of the Mismatch Repair Deficiency between Primary and Recurrent Sites of Uterine Cancers (088)
Daniel Spinosa et al.
GYNECOLOGIC ONCOLOGY (2022)
Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies
Linyuan Wang et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2022)
New approaches for targeting platinum-resistant ovarian cancer
Michelle McMullen et al.
SEMINARS IN CANCER BIOLOGY (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer
Elizabeth M. Swisher et al.
GYNECOLOGIC ONCOLOGY (2021)
Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
Joyce F. Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Wee1 Inhibition in Recurrent Serous Uterine Cancer: Science Paving the Way in a Challenging Disease
Ainhoa Madariaga et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M. Swisher et al.
NATURE COMMUNICATIONS (2021)
A randomized, phase ii study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer
B.J. Rimel
GYNECOLOGIC ONCOLOGY (2021)
A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer
Vicky Makker et al.
GYNECOLOGIC ONCOLOGY (2021)
Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).
Deborah Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
N. Y. L. Ngoi et al.
ESMO OPEN (2021)
Metformin in Gynecologic Cancers: Opening a New Window for Prevention and Treatment?
Ainhoa Madariaga et al.
CLINICAL CANCER RESEARCH (2020)
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)
Neesha C. Dhani et al.
CLINICAL CANCER RESEARCH (2020)
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events
Ainhoa Madariaga et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression
Esther L. Moss et al.
CANCERS (2020)
Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET
A. Oaknin et al.
ANNALS OF ONCOLOGY (2020)
Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas
Gozde Kir et al.
VIRCHOWS ARCHIV (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer A Nonrandomized Phase 1 Clinical Trial
Ana Oaknin et al.
JAMA ONCOLOGY (2020)
Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers
Megan A. Clarke et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer
Panagiotis A. Konstantinopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Clonal hematopoiesis in human aging and disease
Siddhartha Jaiswal et al.
SCIENCE (2019)
Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Marthe M. de Jonge et al.
CLINICAL CANCER RESEARCH (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor
Allison A. Gockley et al.
GYNECOLOGIC ONCOLOGY (2018)
Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease
Ananda Mukherjee et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types
Arielle L. Heeke et al.
JCO PRECISION ONCOLOGY (2018)
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed
Jessica S. Brown et al.
BRITISH JOURNAL OF CANCER (2018)
A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium
Stephanie Lheureux et al.
CLINICAL CANCER RESEARCH (2018)
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
CONTRA: copy number analysis for targeted resequencing
Jason Li et al.
BIOINFORMATICS (2012)
Pathologic Scoring of PTEN Immunohistochemistry in Endometrial Carcinoma is Highly Reproducible
Karuna Garg et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2012)
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
Konstantin J. Dedes et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)